- Home
- BLIN vs BIVI Comparison
BLIN vs BIVI Comparison
Compare BLIN & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIN
- BIVI
- Stock Information
- Founded
- BLIN 2000
- BIVI 2013
- Country
- BLIN United States
- BIVI United States
- Employees
- BLIN N/A
- BIVI N/A
- Industry
- BLIN EDP Services
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- BLIN Technology
- BIVI Health Care
- Exchange
- BLIN Nasdaq
- BIVI Nasdaq
- Market Cap
- BLIN 16.5M
- BIVI 14.2M
- IPO Year
- BLIN 2007
- BIVI N/A
- Fundamental
- Price
- BLIN $1.33
- BIVI $1.77
- Analyst Decision
- BLIN Strong Buy
- BIVI
- Analyst Count
- BLIN 1
- BIVI 0
- Target Price
- BLIN $4.62
- BIVI N/A
- AVG Volume (30 Days)
- BLIN 112.0K
- BIVI 154.7K
- Earning Date
- BLIN 08-14-2025
- BIVI 11-11-2025
- Dividend Yield
- BLIN N/A
- BIVI N/A
- EPS Growth
- BLIN N/A
- BIVI N/A
- EPS
- BLIN N/A
- BIVI N/A
- Revenue
- BLIN $15,375,000.00
- BIVI N/A
- Revenue This Year
- BLIN $2.45
- BIVI N/A
- Revenue Next Year
- BLIN $16.36
- BIVI N/A
- P/E Ratio
- BLIN N/A
- BIVI N/A
- Revenue Growth
- BLIN 0.54
- BIVI N/A
- 52 Week Low
- BLIN $1.04
- BIVI $1.42
- 52 Week High
- BLIN $2.80
- BIVI $38.50
- Technical
- Relative Strength Index (RSI)
- BLIN 48.65
- BIVI 40.12
- Support Level
- BLIN $1.26
- BIVI $1.83
- Resistance Level
- BLIN $1.35
- BIVI $1.94
- Average True Range (ATR)
- BLIN 0.08
- BIVI 0.11
- MACD
- BLIN -0.00
- BIVI -0.00
- Stochastic Oscillator
- BLIN 69.04
- BIVI 6.19
About BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.